Gliclazide PCD Pharma Franchise Company
Cafoli Lifecare offers a well-stocked Gliclazide PCD pharma franchise built on 15 formulations across tablets and metformin combinations, all manufactured at WHO-GMP certified facilities. This gives franchise partners a preferred sulfonylurea antidiabetic line for diabetologists and physicians.
What is Gliclazide?
Gliclazide is a second-generation sulfonylurea antidiabetic that lowers blood glucose by stimulating insulin secretion from pancreatic beta cells. It is often favoured among sulfonylureas for its lower risk of hypoglycaemia and is widely available as a modified-release tablet for once-daily dosing. Read its profile on PubChem.
Therapeutic Applications
Gliclazide is prescribed for type 2 diabetes mellitus to improve glycaemic control, typically added to metformin; the modified-release form and gliclazide-metformin fixed-dose combinations support convenient once-daily regimens. Prescriptions come mainly from diabetologists, endocrinologists and general physicians.
Why Gliclazide is a High-Potential Molecule for Distributors
Among sulfonylureas, gliclazide is often the preferred choice thanks to its favourable hypoglycaemia and cardiovascular-safety profile, so prescribers increasingly select it over older agents. Combined with the vast, lifelong type 2 diabetes population and popular once-daily MR and metformin combinations, this drives strong, continuous repeat demand — making it a dependable, growing antidiabetic molecule for distributors.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- PubChem: Gliclazide
- PubMed: Gliclazide literature
Our formulations of Gliclazide find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: